The funding will be funnelled into an unnamed p53 suppressor-focused oncology Weizmann spinout and ultrasound guidance device maker On-Sight Medical.
Two Israel-based health spinouts of Weizmann Institute of Science have collectively secured $12m in funding from biomedicine developer BioLeaders and VC firm Yozma Group Asia.
The capital includes $10m supplied by BioLeaders, itself backed by Yozma, for a new, as-yet unnamed Weizmann Institute-founded oncology spinout. The investment is anticipated to close in the coming months.
The spinout will focus on exploiting a peptide capable of binding to a tumour suppressor protein called p53.
Dubbed the “guardian” of…
